DE59712322D1 - Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen - Google Patents
Pharmazeutisches Präparat zur Behandlung von BlutgerinnungsstörungenInfo
- Publication number
- DE59712322D1 DE59712322D1 DE59712322T DE59712322T DE59712322D1 DE 59712322 D1 DE59712322 D1 DE 59712322D1 DE 59712322 T DE59712322 T DE 59712322T DE 59712322 T DE59712322 T DE 59712322T DE 59712322 D1 DE59712322 D1 DE 59712322D1
- Authority
- DE
- Germany
- Prior art keywords
- prothrombin
- factor
- composition
- pro
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT51896A AT404673B (de) | 1996-03-20 | 1996-03-20 | Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen |
AT157396A AT407116B (de) | 1996-09-04 | 1996-09-04 | Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen |
AT167396A AT408612B (de) | 1996-09-20 | 1996-09-20 | Verwendung von mindestens 2 gerinnungsfaktoren zur herstellung eines pharmazeutischen präparats |
Publications (1)
Publication Number | Publication Date |
---|---|
DE59712322D1 true DE59712322D1 (de) | 2005-06-30 |
Family
ID=27146406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE59712322T Expired - Lifetime DE59712322D1 (de) | 1996-03-20 | 1997-03-18 | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen |
Country Status (12)
Country | Link |
---|---|
US (5) | US5866122A (de) |
EP (1) | EP0796623B1 (de) |
JP (1) | JPH1045620A (de) |
AT (1) | ATE296109T1 (de) |
AU (3) | AU725442B2 (de) |
CA (1) | CA2200394A1 (de) |
CZ (1) | CZ81997A3 (de) |
DE (1) | DE59712322D1 (de) |
DK (1) | DK0796623T3 (de) |
ES (1) | ES2241030T3 (de) |
HU (1) | HUP9700603A3 (de) |
SI (1) | SI0796623T1 (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE296109T1 (de) * | 1996-03-20 | 2005-06-15 | Baxter Ag | Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen |
ATA159597A (de) * | 1997-09-19 | 2000-09-15 | Immuno Ag | Präparat zur behandlung von blutgerinnungsstörungen |
AT409334B (de) * | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
PL343424A1 (en) | 1998-04-10 | 2001-08-13 | Japan Tobacco Inc | Amidine compounds |
AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
DE19923027C2 (de) * | 1999-05-19 | 2002-09-19 | Aventis Behring Gmbh | Verfahren zur Inaktivierung von Viren |
DE10012732A1 (de) * | 2000-03-18 | 2001-09-20 | Aventis Behring Gmbh | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6689615B1 (en) | 2000-10-04 | 2004-02-10 | James Murto | Methods and devices for processing blood samples |
WO2002055102A1 (en) * | 2001-01-10 | 2002-07-18 | U.S. Army Medical Research & Materiel Command | Compositions for treatment of hemorrhaging with activated factor viia in combination with fibrinogen |
US6825323B2 (en) * | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
US20030124118A1 (en) * | 2001-11-27 | 2003-07-03 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors |
JP2005526004A (ja) * | 2001-11-09 | 2005-09-02 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物 |
EP1446148A1 (de) * | 2001-11-09 | 2004-08-18 | Novo Nordisk A/S | Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure |
US20080057059A1 (en) * | 2001-11-09 | 2008-03-06 | Novo Nordisk Healthcare A/G | Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors |
US20030118580A1 (en) * | 2001-11-09 | 2003-06-26 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides |
JP2005511600A (ja) * | 2001-11-09 | 2005-04-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチドおよびトロンボモジュリンポリペプチドを含む薬学的組成物 |
WO2003039581A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid |
JP2005510516A (ja) * | 2001-11-09 | 2005-04-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチドおよびプロテインs阻害剤を含む薬学的組成物 |
US7291587B2 (en) * | 2001-11-09 | 2007-11-06 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides |
WO2003039579A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides |
US20040048795A1 (en) * | 2002-02-26 | 2004-03-11 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
AU2003242430A1 (en) * | 2002-05-23 | 2003-12-12 | Chugai Seiyaku Kabushiki Kaisha | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
SE0201673L (sv) * | 2002-06-03 | 2003-05-06 | Cemvac System Ab | Anordning för utmatning av en monomer till en med en polymer förfylld blandningsanordning för tillredning av bencement |
SE0203551D0 (sv) * | 2002-12-02 | 2002-12-02 | Biovitrum Ab | Prothrombin purification |
SE0203552D0 (sv) * | 2002-12-02 | 2002-12-02 | Biovitrum Ab | Thrombin concentration |
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
US7214647B2 (en) * | 2004-07-29 | 2007-05-08 | Texas United Chemical Company, Llc. | Method of increasing the low shear rate viscosity of well drilling and servicing fluids containing calcined magnesia bridging solids, the fluids and methods of use |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
CN101124012B (zh) | 2004-12-27 | 2012-09-05 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病的装置 |
CA2602793C (en) * | 2005-04-13 | 2016-11-22 | Astrazeneca Ab | A host cell comprising a vector for production of proteins requiring gamma-carboxylation |
EP1935429A1 (de) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistische therapeutische Anwendung von Prothrombin-Komplexkonzentraten mit FVIII-Konzentraten |
US8206967B2 (en) * | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
AU2009316801C1 (en) | 2008-11-18 | 2015-12-24 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflammatory stimulation |
US8886339B2 (en) | 2009-06-09 | 2014-11-11 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
FR2946348B1 (fr) * | 2009-06-05 | 2011-08-05 | Lab Francais Du Fractionnement | Procede de preparation d'une composition de complexe prothrombique a haut degre de purete |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
EP3636314B1 (de) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Nervenstimulatoren und systeme zur behandlung von chronischer entzündung |
EP2371857A1 (de) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Faktor-XII-Inhibitoren zur Behandlung von interstitieller Pneumonie |
SG188639A1 (en) | 2010-10-06 | 2013-05-31 | Medimmune Ltd | Factor ii and fibrinogen for treatment of haemostatic disorders |
DK2753187T3 (en) * | 2011-08-30 | 2019-01-28 | Caelus Pharmaceuticals B V | Method of preventing and / or treating insulin resistance |
EP2822474B1 (de) | 2012-03-06 | 2018-05-02 | Ferrosan Medical Devices A/S | Druckbehälter mit einer blutstillenden paste |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
CN104349797B (zh) | 2012-06-12 | 2017-10-27 | 弗罗桑医疗设备公司 | 干止血组合物 |
EP3970738A1 (de) * | 2012-07-25 | 2022-03-23 | Bioverativ Therapeutics Inc. | Blutfaktorüberwachungstest und verwendungen davon |
GEP20196990B (en) * | 2013-06-20 | 2019-07-10 | GmbH Baxalta | Method and system for providing a pharmacokinetic drug dosing regime |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
CA2928963C (en) | 2013-12-11 | 2020-10-27 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
TWI653047B (zh) | 2014-03-14 | 2019-03-11 | 百特製藥公司 | 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物 |
AU2015333206B2 (en) | 2014-10-13 | 2019-07-11 | Ferrosan Medical Devices A/S. | Dry composition for use in haemostasis and wound healing |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
RU2705905C2 (ru) | 2014-12-24 | 2019-11-12 | Ферросан Медикал Дивайсиз А/С | Шприц для удерживания и смешивания первого и второго веществ |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
WO2016135719A1 (en) | 2015-02-25 | 2016-09-01 | Omrix Biopharmaceuticals Ltd. | Method for purifying and quantifying thrombin and its degradation polypeptides |
RU2717356C2 (ru) | 2015-07-03 | 2020-03-23 | Ферросан Медикал Дивайсиз А/С | Шприц для удерживания вакуума в состоянии хранения |
CN108472406A (zh) * | 2016-01-07 | 2018-08-31 | 艾欧生物医学有限责任公司 | 减少组织粘连的方法、组合物和试剂盒 |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
EP3405255A4 (de) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | Implantierbare mikrostimulatoren und induktive ladesysteme |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
UA126379C2 (uk) | 2016-04-15 | 2022-09-28 | Баксалта Інкорпорейтед | Спосіб і пристрій для надання фармакокінетичної схеми дозування лікарських препаратів |
US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
AU2018217375A1 (en) * | 2017-02-09 | 2019-06-27 | Csl Behring Gmbh | A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
JP7395113B2 (ja) | 2018-05-09 | 2023-12-11 | フェロサン メディカル デバイシーズ エイ/エス | 止血組成物を調製する方法 |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
AU2019477041A1 (en) * | 2019-12-03 | 2022-07-21 | Guangzhou Bioseal Biotech Co., Ltd. | Pro-thrombin purification |
EP4153053A1 (de) | 2020-05-21 | 2023-03-29 | The Feinstein Institutes for Medical Research | Systeme und verfahren zur vagusnervstimulation |
EP4216928A1 (de) | 2020-09-23 | 2023-08-02 | Omrix Biopharmaceuticals Ltd. | Hämostatische formulierungen und verwendungen davon |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE350726C (de) * | 1922-03-23 | Henry Strauss | Tintenloescher mit Loeschpapierblock | |
DE141262C (de) * | ||||
DE382783C (de) | 1920-01-27 | 1923-12-08 | Gustav Pfarrius | Verfahren zum Wasserabweisendmachen von Holz |
AT350726B (de) * | 1976-08-30 | 1979-06-11 | Immuno Ag | Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma |
DD141262B1 (de) * | 1977-06-09 | 1984-02-29 | Bezirks Inst Fuer Blutspende U | Verfahren zur herstellung eines prothrombinkomplexkonzentrates |
US4287180A (en) * | 1980-01-28 | 1981-09-01 | Baxter Travenol Laboratories, Inc. | Method for treating blood clotting factor inhibitors |
DE3172210D1 (en) * | 1980-05-27 | 1985-10-17 | Miles Lab | Blood coagulation promoting product and process of preparing same |
AT368883B (de) * | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
EP0286198B1 (de) * | 1981-04-27 | 1994-12-14 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Blutgerinnende Enzymzubereitungen |
CA1181987A (en) * | 1981-06-22 | 1985-02-05 | Walter Crooks | Print head for high resolution electrothermal printing apparatus |
US4382083A (en) * | 1981-06-25 | 1983-05-03 | Baxter Travenol Laboratories, Inc. | Therapeutic method for treating blood-clotting defects with factor VIIa |
US4501731A (en) * | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
US4721618A (en) * | 1983-06-27 | 1988-01-26 | Queen's University At Kingston | Method for controlling bleeding |
AT389815B (de) * | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US5028424A (en) * | 1987-10-16 | 1991-07-02 | University Of Georgia Research Foundation | Antibodies to receptor and antigen for natural killer and non-specific cytotoxic cells |
US5120537A (en) * | 1989-06-14 | 1992-06-09 | Oklahoma Medical Research Foundation | Factor xa based anticoagulant compositions |
DK0512011T3 (da) * | 1990-01-26 | 1994-05-09 | Immuno Ag | Blodfaktorer fremstillet ved rekombinant DNA-teknologi, fremgangsmåde til ekspression af blodfaktorerne samt vacciniavirusrekombinanter anvendt ved fremgangsmåden |
AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
DE4142908C2 (de) * | 1991-12-24 | 1994-02-10 | Octapharma Ag Glarus | Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB) |
IT1262899B (it) * | 1992-03-27 | 1996-07-22 | Sclavo Spa | Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano |
WO1994020535A1 (en) * | 1992-12-11 | 1994-09-15 | Corvas International, Inc. | ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR |
DE4325872C1 (de) * | 1993-08-02 | 1994-08-04 | Immuno Ag | Virusinaktivierte Faktor Xa-Präparation |
FR2709227B1 (fr) * | 1993-08-26 | 1995-10-20 | Pellenc Sa | Machine agricole, notamment machine de récolte telle que machine à vendanger. |
DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
DE4416180C2 (de) * | 1994-05-06 | 1997-08-14 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats |
DE4430205A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
ATE296109T1 (de) * | 1996-03-20 | 2005-06-15 | Baxter Ag | Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen |
-
1997
- 1997-03-18 AT AT97890051T patent/ATE296109T1/de active
- 1997-03-18 DK DK97890051T patent/DK0796623T3/da active
- 1997-03-18 CZ CZ97819A patent/CZ81997A3/cs unknown
- 1997-03-18 ES ES97890051T patent/ES2241030T3/es not_active Expired - Lifetime
- 1997-03-18 DE DE59712322T patent/DE59712322D1/de not_active Expired - Lifetime
- 1997-03-18 EP EP97890051A patent/EP0796623B1/de not_active Expired - Lifetime
- 1997-03-18 SI SI9730711T patent/SI0796623T1/xx unknown
- 1997-03-18 HU HU9700603A patent/HUP9700603A3/hu unknown
- 1997-03-19 CA CA002200394A patent/CA2200394A1/en not_active Abandoned
- 1997-03-20 US US08/821,763 patent/US5866122A/en not_active Expired - Lifetime
- 1997-03-20 AU AU16451/97A patent/AU725442B2/en not_active Expired
- 1997-03-21 JP JP9108013A patent/JPH1045620A/ja active Pending
-
1998
- 1998-10-06 US US09/165,745 patent/US6039945A/en not_active Expired - Lifetime
-
1999
- 1999-02-05 US US09/245,339 patent/US6165974A/en not_active Expired - Lifetime
- 1999-02-05 US US09/244,762 patent/US6099837A/en not_active Expired - Lifetime
-
2000
- 2000-03-08 US US09/521,219 patent/US6224862B1/en not_active Expired - Lifetime
- 2000-11-24 AU AU71856/00A patent/AU763466B2/en not_active Expired
-
2003
- 2003-06-02 AU AU2003204479A patent/AU2003204479B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AU2003204479A1 (en) | 2003-06-26 |
ES2241030T3 (es) | 2005-10-16 |
ATE296109T1 (de) | 2005-06-15 |
US6224862B1 (en) | 2001-05-01 |
DK0796623T3 (da) | 2005-08-01 |
HUP9700603A3 (en) | 2001-08-28 |
US6039945A (en) | 2000-03-21 |
JPH1045620A (ja) | 1998-02-17 |
AU763466B2 (en) | 2003-07-24 |
CA2200394A1 (en) | 1997-09-20 |
AU2003204479B2 (en) | 2006-02-23 |
EP0796623B1 (de) | 2005-05-25 |
AU725442B2 (en) | 2000-10-12 |
AU1645197A (en) | 1997-09-25 |
HUP9700603A1 (hu) | 1999-06-28 |
US6165974A (en) | 2000-12-26 |
SI0796623T1 (en) | 2005-10-31 |
US5866122A (en) | 1999-02-02 |
EP0796623A3 (de) | 2000-05-17 |
CZ81997A3 (en) | 1997-10-15 |
US6099837A (en) | 2000-08-08 |
HU9700603D0 (en) | 1997-05-28 |
EP0796623A2 (de) | 1997-09-24 |
AU7185600A (en) | 2001-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE59712322D1 (de) | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen | |
EP0541507B1 (de) | Thrombin sowie Verfahren zu seiner Herstellung | |
FR2679251B1 (fr) | Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique. | |
ATE66374T1 (de) | Zubereitungen und verfahren zur behandlung von blutungsstoerungen. | |
GR82018B (de) | ||
ID24901A (id) | Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh | |
EP0973544B1 (de) | Immuntolerante prothrombinkomplex-präparation | |
ATE257378T1 (de) | Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen | |
ES2073425T3 (es) | Una nueva glicoproteina de tipo trombomodulina susceptible de ser obtenida a partir de la orina. | |
FI882605A0 (fi) | Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta | |
FI873905A (fi) | Terapeutisk komposition och foerfarande. | |
AU696954B2 (en) | Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications | |
DK0497956T3 (da) | Præparater med reguleret frigivelse | |
ATE77751T1 (de) | Mittel zur behandlung von knochenkrankheiten. | |
AU658238B2 (en) | A process for the production of a virus-free concentrate of thrombin | |
ATE89728T1 (de) | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen. | |
GB9503750D0 (en) | Thrombin preparation | |
ATE203164T1 (de) | Ligninpolymerzusammensetzung zur behandlung von hautproblemen | |
RU2191574C2 (ru) | Лекарственное средство, обладающее регенерирующим и ранозаживляющим действием | |
Honorato | Human blood serum rich in factor V | |
RU2128518C1 (ru) | Способ лечения инфицированных ран | |
EP0841954A1 (de) | Zweifach virusinaktiviertes humanes blutplasma, daraus herstellbare blutplasmaderivate und verfahren zu deren herstellung | |
AT406824B (de) | Immuntolerante prothrombinkomplex-präparation | |
ATE234620T1 (de) | Verwendung von lithium-gluconat zur herstellung eines arzneimittels zur behandlung von herpes und seborrhoischer dermatitis | |
UA28922A (uk) | Спосіб лікування респіраторного дистрес-синдрому дорослих |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |